Back to Search
Start Over
Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People
- Publication Year :
- 2016
-
Abstract
- Aims: The objective of this study was to evaluate the prevalence of the prescription of QT-prolonging drugs at hospital admission and discharge and the risk factors associated with their use in older people (aged 65Âyears and older). Methods: Data were obtained from the REPOSI (REgistro POliterapie SIMI [Società Italiana di Medicina Interna]) registry, which enrolled 4035 patients in 2008 (nÂ=Â1332), 2010 (nÂ=Â1380), and 2012 (nÂ=Â1323). Multivariable logistic regression was performed to determine the risk factors independently associated with QT-prolonging drug use. QT-prolonging drugs were classified by the risk of Torsades de Pointes (TdP) (definite, possible, or conditional) according to the Arizona Center for Education and Research on Therapeutics (AzCERT) classification. Specific drug combinations were also assessed. Results: Among 3906 patients prescribed at least one drug at admission, 2156 (55.2Â%) were taking at least one QT-prolonging drug. Risk factors independently associated with the use of any QT-prolonging drugs were increasing age (odds ratio [OR] 1.02, 95Â% CI 1.01â1.03), multimorbidity (OR 2.69, 95Â% CI 2.33â3.10), hypokalemia (OR 2.79, 95Â% CI 1.32â5.89), atrial fibrillation (OR 1.66, 95Â% CI 1.40â1.98), and heart failure (OR 3.17, 95Â% CI 2.49â4.05). Furosemide, alone or in combination, was the most prescribed drug. Amiodarone was the most prescribed drug with a definite risk of TdP. Both the absolute number of QT-prolonging drugs (2890 vs. 3549) and the number of patients treated with them (2456 vs. 2156) increased at discharge. Among 1808 patients not prescribed QT-prolonging drugs at admission, 35.8Â% were prescribed them at discharge. Conclusions: Despite their risk, QT-prolonging drugs are widely prescribed to hospitalized older persons. The curriculum for both practicing physicians and medical students should be strengthened to provide more education on the appropriate use of drugs in order to improve the management of hospitalized older people.
- Subjects :
- Male
TORSADES-DE-POINTES, INTERVAL PROLONGATION, PATIENT, CIPROFLOXACIN, COHORT, DEATH, MULTIMORBIDITY, AMIODARONE, MORTALITY, AIFA
Amiodarone
030204 cardiovascular system & hematology
CIPROFLOXACIN
Logistic regression
Electrocardiography
0302 clinical medicine
Risk Factors
Torsades de Pointes
Atrial Fibrillation
80 and over
Prevalence
Pharmacology (medical)
030212 general & internal medicine
Aged
Aged, 80 and over
Female
Humans
Long QT Syndrome
Middle Aged
Patient Discharge
Hospitalization
media_common
Torsades de Pointe
Geriatrics and Gerontology
Medicine (all)
DEATH
Cohort
Hospitalized Older People
medicine.drug
Human
Drug
medicine.medical_specialty
media_common.quotation_subject
MULTIMORBIDITY
Torsades de pointes
PATIENT
03 medical and health sciences
Pharmacotherapy
Internal medicine
INTERVAL PROLONGATION
medicine
TORSADES-DE-POINTES
COHORT
Medical prescription
AIFA
business.industry
MORTALITY
Risk Factor
Settore MED/09 - MEDICINA INTERNA
Odds ratio
medicine.disease
QT-Prolonging Drug
Physical therapy
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....8fac3cfb155a76c87da6c6f3edf95d63